Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to ...

Eisai is an established developer of medicines to treat Alzheimer's dementia, most recently claiming approval for its Biogen-partnered anti-amyloid therapy Leqembi (lecanemab), ...

Elix is a Japan-based AI drug discovery company with a mission to "Rethinking drug discovery," providing services to ...

Eisai Europe’s headquarters were expanded to become Eisai Europe, Middle East, Africa and Russia in March 2012. Gary joined Eisai in 2008 as European Commercial Development Director.

Eisai is continuing to advance care in Alzheimer’s disease via this multi-dimensional, yet targeted path to our ultimate goal: prevention and stopping progression.

Eisai and Biogen sought the Food and Drug Administration’s accelerated approval for the amyloid beta-busting drug, lecanemab. Sold under the brand name Leqembi, the drug is priced at $26,500 per ...

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for ...

Eisai Inc. executives recently gave NJBIZ a tour of the company's new 15-story, 332,800-square-foot hub in Nutley. In August, Eisai Inc. cut the ribbon on a 15-story, 332,800-square-foot space ...

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.

Review the current Eisai Co Ltd (4523:XTKS) dividend yield and history to decide if 4523 is the best investment for you. 4523 - Eisai Co Ltd Dividends | Morningstar Morningstar brands and products ...

Eisai Co. said a volunteer died while using the company’s experimental Alzheimer’s drug lecanemab in a clinical trial, but that it wasn’t clear if the death was directly caused by the drug ...